Fujifilm to Invest $200 Million to Expand Cell Therapy Development, Manufacturing Capabilities
December 04 2023 - 11:29PM
Dow Jones News
By Ronnie Harui
Fujifilm plans to invest $200 million in two subsidiaries in the
U.S. to expand its global cell therapy contract development and
manufacturing capabilities, the Japanese conglomerate said
Tuesday.
The investment is earmarked for the new headquarters of Fujifilm
Cellular Dynamics in Wisconsin and the California site of Fujifilm
Diosynth Biotechnologies, Fujifilm said in a statement. The
investment will enable Fujifilm to support the expanding cell
therapy market, which is expected to grow by more than 30% a year
from an estimated $3.3 billion in fiscal 2022, it added.
Cell therapies are a promising treatment with the ability to
augment, repair and replace human biology, including organs,
tissues and cells, Fujifilm said.
Write to Ronnie Harui at ronnie.harui@wsj.com
(END) Dow Jones Newswires
December 04, 2023 23:14 ET (04:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
FUJIFILM (PK) (USOTC:FUJIY)
Historical Stock Chart
From Mar 2024 to Apr 2024
FUJIFILM (PK) (USOTC:FUJIY)
Historical Stock Chart
From Apr 2023 to Apr 2024
